3rd Party Payers Overview:

The purpose of the meeting will be to discuss drivers of U.S. and international 3^rd party payers decisions regarding diagnostics and drug treatments for Alzheimer’s disease (AD) and information that informs this decision-making process.

• Are there ways to improve the design and execution of clinical trials to lead to endpoints that payers can use to evaluate potential utility in diverse populations?
• How do 3^rd party payers define and measure value related to AD drug treatments, biomarkers or other indicators and diagnostics?
• What are the biggest challenges facing 3^rd party payers in evaluating outcome measures used in AD research? 

This meeting will include discussion of current debates and concerns around diagnosis, personalized medicine, treatment, defining populations, and managing costs associated with diagnosis and treatment. Do public and private 3^rd party payers consider alternate outcomes? Do they define value differently? What lessons can be learned from registration studies for diagnostics and AD drugs? We will also consider emerging approaches needed in the study of primary and secondary prevention (presymptomatic AD) and mild cognitive impairment due to AD.

 Participants will include industry, academics, regulatory scientists and payers.